Treatment with the approved therapy Uptravi (selexipag) safely reduces disease severity and improves heart and lung health in people with pulmonary hypertension (PH), according to a review study. Researchers recommended that Uptravi be considered for use in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic…
News
Obstructive sleep apnea (OSA) is common among people with pulmonary hypertension (PH), and PH patients with OSA are more likely to report co-occurring health problems like diabetes and high blood pressure, a new study done at a center in China reports. In fact, the study found that more than…
Step count and heart rate data from wearable sensors can be of use as real-world approximations of common clinical tests of fitness, a study drawing on data from people with pulmonary arterial hypertension (PAH) shows. “Activity tracker-measured health parameters could serve as proxies for clinically measured health parameters of…
Real-world use of Opsumit (macitentan) was generally safe, with few liver-related toxicities seen, according to data from two registries largely made up of pulmonary arterial hypertension (PAH) patients. Collective data from the two registries met a requirement from the U.S. Food and Drug Administration (FDA) for additional real-world safety…
A rare mutation in the GDF2 gene was identified in two siblings, a boy and a girl, with pulmonary arterial hypertension (PAH), according to a recent case report. The mutation, which each child inherited in both gene copies, resulted in a lack of the bone morphogenetic protein (BMP) 9 in the…
Cigarette smoking in men newly diagnosed with pulmonary arterial hypertension (PAH) was associated with a faster time to in-patient hospitalization and death after diagnosis, according to an analysis of the REVEAL study in the U.S. More men smoked than women, and ever-smoking status (someone who has been a cigarette…
The experimental therapy HS135 improved heart function and the remodeling of lung blood vessels in a rat model of pulmonary hypertension (PH). That’s according to data reported by the therapy’s developer, 35Pharma, at the 2022 American Heart Association Scientific Sessions (AHA 2022), held earlier this month in Chicago…
An inhaled form of APN01 (alunacedase alfa), APEIRON Respiratory Therapies (AResT)’s investigational therapy for certain lung diseases, was safe and well-tolerated in healthy people, according to data from a Phase 1 clinical trial. “In addition to meeting all primary [goals] regarding the safety and tolerability of APN01 via a new…
Virginia Venture Partners — Virginia Innovation Partnership Corporation (VIPC)’s equity investment program — is investing in OxiWear and its modern ear-wearable device that’s designed to continuously monitor blood oxygen levels in people with pulmonary hypertension (PH). The OxiWear device alerts the user through a phone app when there’s…
A short treatment with Remodulin (injectable treprostinil) before initiating Orenitram (oral treprostinil) allows pulmonary arterial hypertension (PAH) patients to achieve double the normal doses of the oral therapy without increasing side effects. These are the findings of a preliminary analysis of top-line data from the Phase…
Patients, caregivers, family members, and friends are set to mark Pulmonary Hypertension Awareness Month, observed each November to call attention to the complex, chronic, progressive disorder. Awareness and education are vital to heightening the recognition, diagnosis, understanding, and management of pulmonary hypertension (PH), a disease associated with high blood…
Children with episodes of fainting due to pulmonary arterial hypertension (PAH) who respond well to a vasodilator given in a challenge test are likely to have better long-term outcomes than those who respond poorly, a long-term records study suggests. A vasodilator challenge is a test to measure blood pressure in…
